Molecular pathways to polyglutamine aggregation

Advances in Experimental Medicine and Biology

Volumn 769, Issue , 2012, Pages 115-124

  Robertson, Amy L ^a   Bottomley, Stephen P ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMYLOID; CELL PROTEIN; OLIGOMER; POLYGLUTAMINE; POLYPEPTIDE;

AMINO TERMINAL SEQUENCE; ARTICLE; BIOACCUMULATION; CARBOXY TERMINAL SEQUENCE; CYTOTOXICITY; DNA FLANKING REGION; HUMAN; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN CONTENT; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; FOURIER TRANSFORM INFRARED SPECTROSCOPY; KINETICS; PROTEIN MISFOLDING; THERMODYNAMICS;

EID: 84934435661     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5434-2_7     Document Type: Article

References (68)

1. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006; 75:333-366.
2. Anfinsen CB. Principles that govern the folding of protein chains. Science 1973; 181(96):223-230.
3. Jahn TR, Radford SE. Folding versus aggregation: polypeptide conformations on competing pathways. Arch Biochem Biophys 2008; 469(1):100-117.
4. Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 2003; 81(11):678-699.
5. Ordway JM, Tallaksen-Greene S, Gutekunst CA et al. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell 1997; 91(6):753-763.
6. Tanaka M, Morishima I, Akagi T et al. Intra- and intermolecular beta-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases. J Biol Chem 2001; 276(48):45470-45475.
7. Robertson AL, Horne J, Ellisdon AM et al. The structural impact of a polyglutamine tract is location-dependent. Biophys J 2008; 95(12):5922-5930.
8. Ferrone F. Analysis of protein aggregation kinetics. Methods Enzymol 1999; 309:256-274.
9. Kheterpal I, Cook KD, Wetzel R. Hydrogen/deuterium exchange mass spectrometry analysis of protein aggregates. Methods Enzymol 2006; 413:140-166.
10. Chen S, Ferrone FA, Wetzel R. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci U S A 2002; 99(18):11884-11889.
11. Ellisdon AM, Pearce MC, Bottomley SP. Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein. J Mol Biol 2007; 368(2):595-605.
12. Ignatova Z, Gierasch LM. Extended polyglutamine tracts cause aggregation and structural perturbation of an adjacent beta barrel protein. J Biol Chem 2006; 281(18):12959-12967.
13. Bhattacharyya AM, Thakur AK, Wetzel R. polyglutamine aggregation nucleation: thermodynamics of a highly unfavorable protein folding reaction. Proc Natl Acad Sci U S A 2005; 102(43):15400-15405.
14. Wang X, Vitalis A, Wyczalkowski MA et al. Characterizing the conformational ensemble of monomeric polyglutamine. Proteins 2006; 63(2):297-311.
15. Vitalis A, Lyle N, Pappu RV. Thermodynamics of beta-sheet formation in polyglutamine. Biophys J 2009; 97(1):303-311.
16. Dumoulin M, Canet D, Last AM et al. Reduced global co-operativity is a common feature underlying the amyloidogenicity of pathogenic lysozyme mutations. J Mol Biol 2005; 346(3):773-788.
17. Booth DR, Sunde M, Bellotti V et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloidfibrillogenesis. Nature 1997; 385(6619):787-793.
18. Faux NG, Bottomley SP, Lesk AM et al. Functional insights from the distribution and role of homopeptide repeat-containing proteins. Genome Res 2005; 15(4):537-551.
19. Chow MK, Ellisdon AM, Cabrita LD et al. Polyglutamine expansion in ataxin-3 does not affect protein stability: implications for misfolding and disease. J Biol Chem 2004; 279(46):47643-47651.
20. Wellington CL, Ellerby LM, Hackam AS et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 1998; 273(15):9158-9167.
21. Goti D, Katzen SM, Mez J et al. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci 2004; 24(45):10266-10279.
22. Nucifora FC Jr, Ellerby LM, Wellington CL et al. Nuclear localization of a noncaspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. J Biol Chem 2003; 278(15):13047-13055.
23. Rambaran RN, Serpell LC. Amyloid fibrils: abnormal protein assembly. Prion 2008; 2(3):112-117.
24. Wanker EE, Scherzinger E, Heiser V et al. Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates. Methods Enzymol 1999; 309:375-386.
25. Perutz MF, Johnson T, Suzuki M et al. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A 1994; 91(12):5355-5358.
26. Uversky VN. Amyloidogenesis of natively unfolded proteins. Curr Alzheimer Res 2008; 5(3):260-287.
27. Legleiter J, Mitchell E, Lotz GP et al. Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J Biol Chem 2010; 285(19):14777-14790.
28. La Spada AR, Wilson EM, Lubahn DB et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352(6330):77-79.
29. Banfi S, Servadio A, Chung MY et al. Identification and characterization of the gene causing type 1 spinocerebellar ataxia. Nat Genet 1994; 7(4):513-520.
30. Benomar A, Krols L, Stevanin G et al. The gene for autosomal dominant cerebellar ataxia with pigmentary macular dystrophy maps to chromosome 3p12-p21.1. Nat Genet 1995; 10(1):84-88.
31. David G, Abbas N, Stevanin G et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet 1997; 17(1):65-70.
32. Takahashi Y, Okamoto Y, Popiel HA et al. Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy. J Biol Chem 2007; 282(33):24039-24048.
33. Kayed R, Head E, Thompson JL et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300(5618):486-489.
34. Ding TT, Lee SJ, Rochet JC et al. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 2002; 41(32):10209-10217.
35. Hyun DH, Lee M, Hattori N et al. Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem 2002; 277(32):28572-28577.
36. Kheterpal I, Chen M, Cook KD et al. Structural differences in Abeta amyloid protofibrils and fibrils mapped by hydrogen exchange - mass spectrometry with on-line proteolytic fragmentation. J Mol Biol 2006; 361(4):785-795.
37. Myers SL, Thomson NH, Radford SE et al. Investigating the structural properties of amyloid-like fibrils formed in vitro from beta2-microglobulin using limited proteolysis and electrospray ionisation mass spectrometry. Rapid Commun Mass Spectrom 2006; 20(11):1628-1636.
38. Kaylor J, Bodner N, Edridge S et al. Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein. J Mol Biol 2005; 353(2):357-372.
39. O'Sullivan DB, Jones CE, Abdelraheim SR et al. NMR characterization of the pH 4 beta-intermediate of the prion protein: the N-terminal half of the protein remains unstructured and retains a high degree of flexibility. Biochem J 2007; 401(2):533-540.
40. Yu L, Edalji R, Harlan JE et al. Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry 2009; 48(9):1870-1877.
41. Huang H, Milojevic J, Melacini G. Analysis and optimization of saturation transfer difference NMR experiments designed to map early self-association events in amyloidogenic peptides. J Phys Chem B 2008; 112(18):5795-5802.
42. Orte A, Birkett NR, Clarke RW et al. Direct characterization of amyloidogenic oligomers by single-molecule fluorescence. Proc Natl Acad SciUSA 2008; 105(38):14424-14429.
43. Thakur AK, Jayaraman M, Mishra R et al. Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat Struct Mol Biol 2009; 16(4):380-389.
44. Ellisdon AM, Thomas B, Bottomley SP. The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J Biol Chem 2006; 281(25):16888-16896.
45. Nozaki K, Onodera O, Takano H et al. Amino acid sequences flanking polyglutamine stretches influence their potential for aggregate formation. Neuroreport 2001; 12(15):3357-3364.
46. Bhattacharyya A, Thakur AK, Chellgren VM et al. Oligoproline effects on polyglutamine conformation and aggregation. J Mol Biol 2006; 355(3):524-535.
47. De Chiara C, Menon RP, Adinolfi S et al. The AXH domain adopts alternative folds the solution structure of HBP1 AXH. Structure 2005; 13(5):743-753.
48. Burright EN, Davidson JD, Duvick LA et al. Identification of a self-association region within the SCA1 gene product, ataxin-1. Hum Mol Genet 1997; 6(4):513-518.
49. DiFiglia M, Sapp E, Chase KO et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277(5334):1990-1993.
50. Ellerby LM, Andrusiak RL, Wellington CL et al. Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem 1999; 274(13):8730-8736.
51. Klein FA, Pastore A, Masino L et al. Pathogenic and nonpathogenic polyglutamine tracts have similar structural properties: towards a length-dependent toxicity gradient. J Mol Biol 2007; 371(1):235-244.
52. Busch A, Engemann S, Lurz R et al. Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease. J Biol Chem 2003; 278(42):41452-41461.
53. Masino L, Nicastro G, Menon RP et al. Characterization ofthe structure and the amyloidogenic properties of the Josephin domain ofthe polyglutamine-containing protein ataxin-3. J Mol Biol 2004; 344(4):1021-1035.
54. Robertson AL, Headey SJ, Saunders HM et al. Small heat-shock proteins interact with a flanking domain to suppress polyglutamine aggregation. Proc Natl Acad Sci U S A 2010; 107(23):10424-10429.
55. Klein AF, Ebihara M, Alexander C et al. PABPN1 polyalanine tract deletion and long expansions modify its aggregation pattern and expression. Exp Cell Res 2008; 314(8):1652-1666.
56. Fernandez-Bellot E, Guillemet E, Baudin-Baillieu A et al. Characterization of the interaction domains of Ure2p, a prion-like protein of yeast. Biochem J 1999; 338(Pt 2):403-407.
57. Nagai Y, Tucker T, Ren H et al. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J Biol Chem 2000; 275(14):10437-10442.
58. Orr CR, Montie HL, Liu Y et al. An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J Biol Chem 2010.
59. Snyder-Keller A, McLear JA, Hathorn T et al. Early or Late-Stage Anti-N-Terminal Huntingtin Intrabody Gene Therapy Reduces Pathological Features in B6.HDR6/1 Mice. J Neuropathol Exp Neurol 2010.
60. Southwell AL, Khoshnan A, Dunn DE et al. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci 2008; 28(36):9013-9020.
61. Legleiter J, Lotz GP, Miller J et al. Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J Biol Chem 2009; 284(32):21647-21658.
62. Muchowski PJ, Schaffar G, Sittler A et al. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad SciUSA2000; 97(14):7841-7846.
63. Behrends C, Langer CA, Boteva R et al. Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol Cell 2006; 23(6):887-897.
64. Herbst M, Wanker EE. Small molecule inducers of heat-shock response reduce polyQ-mediated huntingtin aggregation. A possible therapeutic strategy. Neurodegener Dis 2007; 4(2-3):254-260.
65. Waza M, Adachi H, Katsuno M et al. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J Mol Med 2006; 84(8):635-646.
66. Heiser V, Engemann S, Brocker W et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors ofHuntington's disease by using an automated filter retardation assay. Proc Natl Acad Sci U S A 2002; 99 Suppl 4:16400-16406.
67. Zhang X, Smith DL, Meriin AB et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A 2005; 102(3):892-897.
68. Ehrnhoefer DE, Duennwald M, Markovic P et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet 2006; 15(18):2743-2751.